3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
219
Neoplasms
15
Neoplasm Metastasis
12
Carcinoma, Intraductal, Noninfiltrating
10
Breast Neoplasms, Male
7
Breast Diseases
7
Breast Carcinoma In Situ
7
Advanced Breast Cancer
6
Triple Negative Breast Neoplasms
5
Ovarian Neoplasms
5
Endometrial Neoplasms
5
Neoplasms by Site
3
Breast Cancer Metastatic
3
Uterine Cervical Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasm Female
2
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Skin Diseases
1
Sexual Dysfunctions, Psychological
1
Sexual Dysfunction, Physiological
1
Seizures
1
Sarcoma
1
Recurrence
1
Quality of Life
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Osteoporosis
1
Multiple Endocrine Neoplasia Type 1
1
Low Grade Serous Ovarian Cancer
1
Interventions
binimetinib
2
Sodium Chloride
2
Aminolevulinic Acid
2
palbociclib
1
methyl 5-aminolevulinate
1
ipatasertib
1
exemestane
1
encorafenib
1
baricitinib
1
atezolizumab
1
Vemurafenib
1
VP-102
1
Trabectedin
1
Spironolactone
1
Radiotherapy
1
Radiation
1
Photochemotherapy
1
Paclitaxel
1
Low-Level Light Therapy
1
Leuprolide
1
Injections, Intradermal
1
Gonadotropin-Releasing Hormone
1
Fluorouracil
1
Floderm topical cream
1
Everolimus
1
Equipment and Supplies
1
Docetaxel
1
Dacarbazine
1
Cetuximab
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Skin Diseases
×
Anastrozole
×
Clear all
NCT04711252
2025-10-14
SERENA-4
AstraZeneca
Phase 3
Active not recruiting
1,370 enrolled